Which has preferable earnings & valuation, CRDL or SGP?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A

Is CRDL or SGP more profitable?

Spyglass Pharma's return on equity of -62.40% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Spyglass Pharma N/A -62.40% -24.83%

Does the media refer more to CRDL or COLL?

In the previous week, Collegium Pharmaceutical had 9 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 2 mentions for Cardiol Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.09 beat Cardiol Therapeutics' score of 0.96 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRDL or TBPH?

In the previous week, Theravance Biopharma had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Theravance Biopharma and 2 mentions for Cardiol Therapeutics. Theravance Biopharma's average media sentiment score of 1.57 beat Cardiol Therapeutics' score of 0.96 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, CRDL or ACHV?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A

Is CRDL or ACHV more profitable?

Cardiol Therapeutics' return on equity of -180.44% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Achieve Life Sciences N/A -511.12% -82.35%

Does the media favor CRDL or ACHV?

In the previous week, Achieve Life Sciences had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Achieve Life Sciences and 2 mentions for Cardiol Therapeutics. Achieve Life Sciences' average media sentiment score of 1.33 beat Cardiol Therapeutics' score of 0.96 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Achieve Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, CRDL or GLAS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Glass House Brands N/A N/A N/A N/A N/A

Is CRDL or GLAS more profitable?

Glass House Brands' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Glass House Brands N/A N/A N/A

Does the media refer more to CRDL or GLAS?

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 2 articles in the media. Cardiol Therapeutics' average media sentiment score of 0.96 beat Glass House Brands' score of 0.38 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glass House Brands 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cardiol Therapeutics (CRDL) Competitors

$1.94 -0.12 (-5.83%)

As of 08/28/2026 04:00 PM Eastern

Compare

CRDL vs. SGP, COLL, TBPH, ACHV, and GLAS

Should you buy Cardiol Therapeutics stock or one of its competitors? Cardiol Therapeutics's main competitors and comparable companies include Spyglass Pharma (SGP), Collegium Pharmaceutical (COLL), Theravance Biopharma (TBPH), Achieve Life Sciences (ACHV), and Glass House Brands (GLAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cardiol Therapeutics compare to Spyglass Pharma?

Cardiol Therapeutics (NASDAQ:CRDL) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Spyglass Pharma's return on equity of -62.40% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Spyglass Pharma	N/A	-62.40%	-24.83%

Cardiol Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 415.46%. Spyglass Pharma has a consensus target price of $44.00, suggesting a potential upside of 66.54%. Given Cardiol Therapeutics' higher possible upside, equities research analysts plainly believe Cardiol Therapeutics is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Spyglass Pharma. MarketBeat recorded 2 mentions for Cardiol Therapeutics and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat Cardiol Therapeutics' score of 0.96 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Positive
Spyglass Pharma	Very Positive

Summary

Cardiol Therapeutics beats Spyglass Pharma on 6 of the 11 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Collegium Pharmaceutical?

Cardiol Therapeutics (NASDAQ:CRDL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Collegium Pharmaceutical had 9 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 2 mentions for Cardiol Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.09 beat Cardiol Therapeutics' score of 0.96 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 415.46%. Collegium Pharmaceutical has a consensus target price of $51.00, suggesting a potential upside of 101.18%. Given Cardiol Therapeutics' higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Collegium Pharmaceutical	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

Collegium Pharmaceutical has a net margin of 5.93% compared to Cardiol Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cardiol Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Collegium Pharmaceutical	$780.57M	1.06	$62.87M	$1.24	20.44

Summary

Collegium Pharmaceutical beats Cardiol Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Theravance Biopharma?

Cardiol Therapeutics (NASDAQ:CRDL) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Theravance Biopharma had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Theravance Biopharma and 2 mentions for Cardiol Therapeutics. Theravance Biopharma's average media sentiment score of 1.57 beat Cardiol Therapeutics' score of 0.96 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Theravance Biopharma has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Theravance Biopharma	$107.46M	8.24	$105.89M	$1.01	16.88

Theravance Biopharma has a net margin of 51.58% compared to Cardiol Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Cardiol Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cardiol Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 415.46%. Theravance Biopharma has a consensus target price of $19.40, suggesting a potential upside of 13.78%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25

Summary

Theravance Biopharma beats Cardiol Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Achieve Life Sciences?

Cardiol Therapeutics (NASDAQ:CRDL) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cardiol Therapeutics' return on equity of -180.44% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Cardiol Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 415.46%. Achieve Life Sciences has a consensus target price of $15.00, indicating a potential upside of 85.19%. Given Cardiol Therapeutics' higher probable upside, equities analysts plainly believe Cardiol Therapeutics is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market.

In the previous week, Achieve Life Sciences had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Achieve Life Sciences and 2 mentions for Cardiol Therapeutics. Achieve Life Sciences' average media sentiment score of 1.33 beat Cardiol Therapeutics' score of 0.96 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Achieve Life Sciences beats Cardiol Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Glass House Brands?

Cardiol Therapeutics (NASDAQ:CRDL) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Cardiol Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 415.46%. Glass House Brands has a consensus target price of $16.00, indicating a potential upside of 61.29%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Glass House Brands	N/A	N/A	N/A	N/A	N/A

Glass House Brands' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Glass House Brands	N/A	N/A	N/A

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 2 articles in the media. Cardiol Therapeutics' average media sentiment score of 0.96 beat Glass House Brands' score of 0.38 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glass House Brands	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cardiol Therapeutics beats Glass House Brands on 6 of the 8 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$224.82M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	N/A	787.65	273.16	25.45
Price / Sales	N/A	789.00	640.71	89.43
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	17.64	11.97	12.98	6.14
Net Income	-$24.20M	$2.83B	$3.48B	$348.86M
7 Day Performance	4.30%	0.39%	0.13%	-0.80%
1 Month Performance	59.67%	5.34%	7.08%	4.13%
1 Year Performance	79.63%	6.05%	24.67%	15.17%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	2.6748 of 5 stars	$1.94 -5.8%	$10.00 +415.5%	+79.6%	$224.82M	N/A	N/A	20	Analyst Forecast
SGP Spyglass Pharma	2.6954 of 5 stars	$26.26 -0.9%	$44.00 +67.5%	N/A	$889.35M	N/A	N/A	65	Positive News
COLL Collegium Pharmaceutical	3.0246 of 5 stars	$27.14 +0.1%	$51.00 +87.9%	-34.7%	$886.93M	$780.57M	21.97	210	News Coverage Positive News
TBPH Theravance Biopharma	3.9089 of 5 stars	$17.01 0.0%	$19.40 +14.1%	+22.8%	$882.90M	$107.46M	16.84	110	News Coverage Short Interest Decrease
ACHV Achieve Life Sciences	3.2364 of 5 stars	$8.04 +1.3%	$15.00 +86.5%	+171.8%	$827.93M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDL) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. SGP, COLL, TBPH, ACHV, and GLAS

How does Cardiol Therapeutics compare to Spyglass Pharma?

Summary

How does Cardiol Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Cardiol Therapeutics compare to Theravance Biopharma?

Summary

How does Cardiol Therapeutics compare to Achieve Life Sciences?

Summary

How does Cardiol Therapeutics compare to Glass House Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. SGP, COLL, TBPH, ACHV, and GLAS

How does Cardiol Therapeutics compare to Spyglass Pharma?

Is CRDL or SGP more profitable?

Do analysts recommend CRDL or SGP?

Do institutionals & insiders hold more shares of CRDL or SGP?

Which has preferable earnings & valuation, CRDL or SGP?

Does the media prefer CRDL or SGP?

Summary

How does Cardiol Therapeutics compare to Collegium Pharmaceutical?

Does the media refer more to CRDL or COLL?

Do analysts rate CRDL or COLL?

Is CRDL or COLL more profitable?

Do insiders & institutionals hold more shares of CRDL or COLL?

Which has more volatility and risk, CRDL or COLL?

Which has better valuation & earnings, CRDL or COLL?

Summary

How does Cardiol Therapeutics compare to Theravance Biopharma?

Does the media favor CRDL or TBPH?

Which has higher earnings and valuation, CRDL or TBPH?

Is CRDL or TBPH more profitable?

Which has more risk and volatility, CRDL or TBPH?

Do insiders & institutionals have more ownership in CRDL or TBPH?

Do analysts recommend CRDL or TBPH?

Summary

How does Cardiol Therapeutics compare to Achieve Life Sciences?

Do insiders and institutionals believe in CRDL or ACHV?

Is CRDL or ACHV more profitable?

Do analysts recommend CRDL or ACHV?

Which has stronger earnings and valuation, CRDL or ACHV?

Which has more risk & volatility, CRDL or ACHV?

Does the media favor CRDL or ACHV?

Summary

How does Cardiol Therapeutics compare to Glass House Brands?

Do analysts rate CRDL or GLAS?

Do institutionals and insiders believe in CRDL or GLAS?

Which has better earnings and valuation, CRDL or GLAS?

Is CRDL or GLAS more profitable?

Does the media refer more to CRDL or GLAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools